Calcilytix
https://calcilytix.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Calcilytix
BridgeBio's Calcilytix Sees POC For Encaleret And Options To Discuss With FDA
Calcilytix chief medical officer Jonathan Fox talked to Scrip about the development plans for encaleret for the rare form of hypoparathyroidism.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice